Your session is about to expire
← Back to Search
Imetelstat + Ruxolitinib for Myelofibrosis
Study Summary
This trial is studying the recommended dosage of a combination of imetelstat and ruxolitinib to treat myelofibrosis, as well as the safety and effectiveness of this dosage.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2018 Phase 2 trial • 80 Patients • NCT01731951Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have HIV or a severe infection needing IV antibiotics.I can take care of myself and am up and about more than half of my waking hours.I have had surgery to remove all or part of my spleen.I have been treated with imetelstat before.I have a serious heart condition.I have been diagnosed with a type of myelofibrosis according to specific health criteria.I do not have active hepatitis needing treatment or liver disease, unless it's due to myelofibrosis.I have had a stem cell transplant in the past.I have been treated with a JAK inhibitor before.My myelofibrosis is classified as intermediate-1, intermediate-2, or high-risk.I am allergic to imetelstat, ruxolitinib, or their ingredients.I have symptoms or an enlarged spleen due to myelofibrosis.I cannot or do not want to have a stem cell transplant.I haven't taken any experimental drugs or specific treatments listed within the last 14 days.I have not had major surgery in the last 28 days.I have not had any cancer except for non-melanoma skin cancer, lentigo maligna, or cervical carcinoma in situ in the last 3 years.
- Group 1: Imetelstat + Ruxolitinib
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many people are partaking in this trial's treatments?
"Affirmative. The clinical trial data available on clinicaltrials.gov indicates that this medical experiment, first launched on May 4th 2022, is actively looking for participants to join its ranks. This study requires 41 people and 3 separate sites in total."
Are any recruitment opportunities available for this clinical trial currently?
"Affirmative. Per the information accessible on clinicaltrials.gov, this medical study is presently looking for participants and was initially posted on May 4th 2022. The trial has since been updated to accept up to 41 patients from three different sites."
Is Imetelstat a viable solution in terms of patient safety?
"Imetelstat has only been tested in a Phase 1 trial, so its safety is rated as a score of one. This indicates that there is limited evidence to support the drug's efficacy and security profile."
Share this study with friends
Copy Link
Messenger